The following terms were used: “Sodium-Glucose Cotransporter-2 Inhibitors,” “SGLT2 Inhibitors,” “SGLT2i,” “Sodium-Glucose Transporter 2 Inhibitors,” “Sodium-Glucose Cotransporter Type 2 Inhibitors,” “Gliflozins,” “Dapagliflozin,” “Heart Failure with Preserved Ejection Fraction,” and “HFpEF.” Then, all authors summarized the recent articles based on their focus on the clinical significance and therapeutic applications of SGLT2 inhibitors in HFpEF. This evidence concerns the gene SLC5A2 and heart failure.